TSJCI Annual Report 2021

Trinity St James’s Cancer Institute Annual Report 2021 23 Section 2.0 Cancer Clinical Trials 2.1 Key Developments during 2021 • The main goal for 2021 was to re-locate the Cancer Clinical Trial Unit (CCTU) clinics to the Clinical Research Facility (CRF) and this was achieved. The relocation has improved the patient experience, increased efficiencies and allowed continued collaboration with the CRF. • With 11 patients enrolled in 2021 we were the joint 2nd highest recruiting site globally for the international CLL17 trial “ A phase 3 multicenter, randomised, prospective, open- label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia CLL ”. • The Trinity Academic Cancer Cluster (TACC) was awarded an infrastructure grant from the Health Research Board in 2021. The award was €2,342,983 over five years, commencing in January 2022. The TACC cluster consists of St James’s Hospital, Tallaght University Hospital and Tullamore Hospital. 2.2 Key Priorities for 2022 • Our main goal is to maximise patient recruitment and to have 50 open trials by the end of 2022. • To increase collaboration across the cancer clinical trial units in the cluster and to continue to provide innovative treatment options for our patients.